SCHEMBL1256010

SCHEMBL1256010

O=C(Nc1nc(-c2ccco2)c(N2CCOCC2)s1)C1CCN(C(=O)N2CCOCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
KMT2A Q03164 6/20 0.54
KDM4E B2RXH2 5/20 0.54
POLB P06746 4/20 0.54
MEN1 O00255 4/20 0.54
MAPT P10636 4/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
LMNA P02545 2/20 0.54
PKM P14618 1/20 0.54
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
PTPN7 P35236 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
ROCK2 O75116 1/20 0.44
HSD17B10 Q99714 5/20 0.44
ADORA2A P29274 3/20 0.44
ADORA1 P30542 3/20 0.44
USP2 O75604 3/20 0.44
ADORA3 P0DMS8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1254096 0.92 ALDH1A1 (0.53) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1256231 0.89 ALDH1A1 (0.51) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1255293 0.88 KMT2A (0.49) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1255331 0.88 ALDH1A1 (0.55) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1256113 0.87 KDM4E (0.52) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1256443 0.86 ALDH1A1 (0.52) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1254200 0.85 MAPT (0.55) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1254068 0.84 KDM4E (0.49) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1255391 0.84 ALDH1A1 (0.49) ALDH1A1KMT2AKDM4EPOLBMEN1
SCHEMBL1256720 0.84 ALDH1A1 (0.52) ALDH1A1KMT2AKDM4EPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 ALDH1A1 1344/4885KMT2A 992/4885KDM4E 4495/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA ALDH1A1 769/4885KMT2A 1022/4885KDM4E 4497/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 ALDH1A1 1290/4885KMT2A 4222/4885KDM4E 4728/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 ALDH1A1 2843/4885KMT2A 3885/4885KDM4E 4715/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 ALDH1A1 638/4885KMT2A 763/4885KDM4E 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.